121124-94-5

Basic information

• Product Name: 2-(BENZYLOXY)-5-BROMOBENZALDEHYDE
• Synonyms: CHEMBRDG-BB 3005903;AURORA 10093;ART-CHEM-BB B005903;2-(BENZYLOXY)-5-BROMOBENZALDEHYDE;AKOS B005903;AKOS BBS-00006697;OTAVA-BB BB7014211657;2-(benzyloxy)-5-bromobenzaldehyde(SALTDATA: FREE)
• CAS NO: 121124-94-5
• Molecular Formula: C₁₄H₁₁BrO₂
• Molecular Weight: 291.14
• Mol File: 121124-94-5.mol

Chemical Properties

• Melting Point: 73-74 °C
• Boiling Point: 405.3 °C at 760 mmHg
• Flash Point: 198.9 °C
• Appearance: /
• Density: 1.441 g/cm³
• Vapor Pressure: 8.86E-07mmHg at 25°C
• Refractive Index: 1.629
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-(BENZYLOXY)-5-BROMOBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(BENZYLOXY)-5-BROMOBENZALDEHYDE(121124-94-5)
• EPA Substance Registry System: 2-(BENZYLOXY)-5-BROMOBENZALDEHYDE(121124-94-5)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 121124-94-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-(Benzyloxy)-5-bromobenzaldehyde is utilized as a key intermediate in organic synthesis for the production of various organic compounds. Its unique structure allows for the formation of diverse chemical entities through reactions such as condensation, reduction, and substitution.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 2-(Benzyloxy)-5-bromobenzaldehyde is employed as a reagent in the preparation of a range of pharmaceuticals. Its presence in the synthesis process contributes to the development of new drugs with potential therapeutic applications.
Used in Fine Chemicals Production:
2-(BENZYLOXY)-5-BROMOBENZALDEHYDE also finds application in the production of fine chemicals, where its specific chemical properties are harnessed to create high-quality specialty chemicals used across various industries.
Used in Antimicrobial Research:
2-(Benzyloxy)-5-bromobenzaldehyde has been investigated for its antimicrobial properties, indicating its potential use as an agent against various microorganisms, which could be beneficial in the development of new antimicrobial agents.
Used in Antineoplastic Studies:
Furthermore, studies have explored the compound's antineoplastic effects, suggesting its possible application in cancer research and treatment. This could lead to the discovery of new therapeutic approaches for managing neoplastic diseases.

InChI:InChI=1/C14H11BrO2/c15-13-6-7-14(12(8-13)9-16)17-10-11-4-2-1-3-5-11/h1-9H,10H2

Upstream product

• 5896-17-3 2-(phenylmethoxy)benzaldehyde 
• 7726-95-6 bromine 
• 127-09-3 sodium acetate 
• 64-19-7 acetic acid 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 584-08-7 potassium carbonate 
• 1761-61-1 5-bromosalicyclaldehyde 
• 110-71-4 1,2-dimethoxyethane 

Downstream Products

• 121124-96-7 2-(2-(benzyloxy)-5-bromophenyl)-1,3-dioxane 
• 515160-04-0 3-(2-benzyloxy-5-bromophenyl)-3-hydroxy-2-methylenepropanenitrile 
• 796046-85-0 (Z)-5-(2-benzyloxy-5-bromobenzylidene)-2-thioxo-thiazolidin-4-one 
• 632627-73-7 1-[5-bromo-2-(benzyloxy)phenyl]-hexane-1,4-dione 
• 916441-90-2 2-(4-benzyloxy-3-hydroxymethyl-phenyl)-2-methyl-propionic acid methyl ester 
• 916441-99-1 2-[3-hydroxymethyl-4-(pyridin-2-ylmethoxy)-phenyl]-2-methyl-propionic acid methyl ester 
• 916441-83-3 2-[3-hydroxymethyl-4-(pyridin-3-ylmethoxy)-phenyl]-2-methyl-propionic acid methyl ester 
• 916441-77-5 2-[4-hydroxy-3-(2-trimethylsilanyl-ethoxymethoxymethyl)-phenyl]-2-methyl-propionic acid methyl ester 
• 916441-57-1 [2-(2-benzyloxy-5-bromo-benzyloxymethoxy)-ethyl]-trimethyl-silane 
• 916441-68-4 2-[4-benzyloxy-3-(2-trimethylsilanyl-ethoxymethoxymethyl)-phenyl]-2-methyl-propionic acid methyl ester 
• 916441-80-0 2-methyl-2-[4-(pyridin-2-ylmethoxy)-3-(2-trimethylsilanyl-ethoxymethoxymethyl)-phenyl]-propionic acid methyl ester 
• 916441-59-3 3-[4-bromo-2-(tert-butyl-diphenyl-silanyloxymethyl)-phenoxymethyl]-pyridine 
• 916441-65-1 2-[3-(tert-butyl-diphenyl-silanyloxymethyl)-4-(pyridin-3-ylmethoxy)-phenyl]-2-methyl-propionic acid methyl ester 
• 146335-33-3 (R)-5-(2-benzyloxy-5-bromo)phenyl (S)-4-(methoxycarbonyl)oxazolidin-2-thione 

Relevant articles and documents

Desymmetrization of Diarylmethylamido Bis(phenols) through Peptide-Catalyzed Bromination: Enantiodivergence as a Consequence of a 2 amu Alteration at an Achiral Residue within the Catalyst

Diarylmethylamido bis(phenols) have been subjected to peptide-catalyzed, enantioselective bromination reactions. Desymmetrization of compounds in this class has been achieved such that enantioenriched products may be isolated with up to 97:3 er. Mechanist

Exploring intermolecular contacts in multi-substituted benzaldehyde derivatives: X-ray, Hirshfeld surface and lattice energy analyses

Crystal structures of six benzaldehyde derivatives (1-6) have been determined and their supramolecular networks were established by an X-ray crystallographic study. The study has shown that the compounds are linked by various intermolecular interactions s

Development of DHQ-based chemical biology probe to profile cellular targets for HBV

Chronic hepatitis B virus (HBV) infection has been a serious public health burden worldwide. Current anti-HBV therapies could not eliminate HBV ultimately. Considering the characteristics of HBV, it is impossible to be entirely cured based on current therapies. Therefore, it is urgently needed to develop novel therapeutic agents with new mechanism of action. The dihydroquinolizinone (DHQ) derivatives exhibited potent anti-HBV activity by decreasing HBV DNA and HBsAg level in an obscure mechanism of action. In this study, we have optimized the DHQ scaffold, developed the photoaffinity probe, with which to identify potential binding proteins.

Choline Hydroxide as a Versatile Medium for Catalyst-Free O-Functionalization of Phenols

A versatile synthetic protocol for benzyl phenyl ether preparation via O-alkylation of phenolic oxygen with readily available benzyl derivatives was demonstrated. The newly designed procedure was carried out using an eco-friendly medium, room-temperature ionic liquid (choline hydroxide), under metal- and base-catalyst-free aerobic conditions. The reaction platform was also successfully applied to phenol protection strategy.

Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability

We have previously reported a series of μ-opioid receptor (MOR) agonist/δ-opioid receptor (DOR) antagonist ligands to serve as potential nonaddictive opioid analgesics. These ligands have been shown to be active in vivo, do not manifest withdrawal syndromes or reward behavior in conditioned-place preference assays in mice, and do not produce dependence. Although these attributes are promising, these analogues exhibit poor metabolic stability in mouse liver microsomes, likely due to the central tetrahydroquinoline scaffold in this series. As such, a structure-activity relationship (SAR) campaign was pursued to improve their metabolic stability. This resulted in a shift from our original bicyclic tetrahydroquinoline core to a monocyclic benzylic-core system. By eliminating one of the rings in this scaffold and exploring the SAR of this new core, two promising analogues were discovered. These analogues (5l and 5m) had potency and efficacy values at MOR better or comparable to morphine, retained their DOR-antagonist properties, and showed a 10-fold improvement in metabolic stability.

IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. For Formula (I) compounds R1, R2, X1, Y1 and n are as defined in the specification. The inventive Formula (I) compounds are inhibitors of the PD-1/PD-L1 protein/protein binding or functional interaction and find utility in any number of therapeutic applications, including but not limited to treatment of proliferative disorders such as cancer and infectious diseases.

FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE

The present invention relates to a fused tricyclic compound and use thereof as a medicament, in particular as a medicament for the treatment and/or prevention of hepatitis B. Specifically, the invention relates to a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variate is as defined in specification. The invention also relates to the use of the compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B.

COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS

The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.

Design and synthesis of novel meta-linked phenylglycine macrocyclic FVIIa inhibitors

Two novel series of meta-linked phenylglycine-based macrocyclic FVIIa inhibitors have been designed to improve the rodent metabolic stability and PK observed with the precursor para-linked phenylglycine macrocycles. Through iterative structure-based design and optimization, the TF/ FVIIa Ki was improved to subnanomolar levels with good clotting activity, metabolic stability, and permeability.

Synthesis and evaluation of 3-hydroxy-3-phenylpropanoate ester-AZT conjugates as potential dual-action HIV-1 Integrase and Reverse Transcriptase inhibitors

Novel 3-hydroxy-3-phenylpropanoate ester-azidothymidine (AZT) conjugates have been prepared using Baylis-Hillman methodology, and their potential as dual-action HIV-1 Integrase and Reverse Transcriptase inhibitors has been explored using enzyme inhibition